BreezeBio

BreezeBio is a biotechnology company developing precision genetic medicines enabled by targeted, non-viral delivery across biologically relevant tissues. Using its proprietary NanoGalaxy platform, the company engineers nanoparticles designed to deliver genetic payloads, including mRNA, to specific cell types, with demonstrated delivery to immune cells and tissues in the heart, lung, and central nervous system. BreezeBio is advancing an internal therapeutic pipeline focused on autoimmune disease and oncology, led by BRZ-101, a program designed to restore immune tolerance in Type 1 Diabetes that is advancing into IND-enabling studies.